Evidence check

What the studies answer—and what they leave open

Most sermorelin research is old, small, and focused on children with diagnosed hormone problems. That is a different question from adult wellness.

Flat geometric illustration of unequal data bars divided by thick black lines in primary colors

Children

The approval trial showed faster growth, with limits

SIZE

The main medical study (called a trial) behind the old approval included 110 children who made too little growth hormone.note

RESULT

The researchers counted growth results for 86 of those children. In those 86, average growth rose from about 4 centimeters a year to about 7 to 8 centimeters a year during the first year.note

LIMIT

The trial had no comparison group: every child got sermorelin, so there was no similar group without it to show how much of the growth the medicine caused. Its patients were also children with a diagnosed shortage, not adults seeking wellness care.note

Comparison

Growth hormone performed better in a direct study

A six-month study compared treatments in 60 children with a particular form of growth hormone deficiency.note

The growth-hormone group reached an average yearly growth rate of 14.6 centimeters, compared with 9.2 to 9.3 centimeters in the sermorelin groups.note

Important detail: that study did not use the same schedule as the old approved sermorelin treatment, so it does not settle every comparison.

Older adults

The adult studies were small and short

Three studies in older adults included only 10 to 19 people each and lasted from 2 to 16 weeks.note

Body fat did not change in either of the two studies that checked it.note

A 16-week study used a slightly changed lab-made version of the same hormone piece, not sermorelin itself, and found no change in sleep quality. Because the medicine was different, it cannot say exactly what sermorelin would do.note

What can be said

Some short studies found that growth hormone, and sometimes IGF-1 (a body signal that rises with it), went up. A higher blood level is not the same as a proven benefit such as less fat or better sleep.

What cannot be claimed

These studies do not establish long-term benefits for fat loss, sleep, energy, or healthy aging.

Next note

Separate known effects from missing data

As of September 2026, there is no current FDA label, the official safety sheet an approved medicine carries.

Open caution notes →

Page notes

  1. PubMed: first-year growth trial in children
  2. PubMed: comparison with growth hormone
  3. PubMed: study in healthy older men
  4. PubMed: study of a related variant in older adults